At $1.15 a share, the offering is being done on a "best efforts" basis. Subject to usual circumstances, the business ...
Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...
This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...
Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of approximately 2.6M shares of common stock. The offering price of ...
Glucotrack, Inc. (Nasdaq: GCTK) disclosed a significant move within its capital structure. This Delaware corporation specializing in medical devices made public a press release involving a 1-for-20 ...
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...
Glucotrack, Inc., a medical technology company specializing in diabetes solutions, announced it has achieved ISO 13485:2016 certification from the British Standards Institute, marking a ...
Glucotrack (NASDAQ:GCTK) on Tuesday reported the successful completion of its first in human clinical study, sending shares up ~60% in the morning trade. This study represents first real-time, ...